Serum insulin and C-peptide concentration and breast cancer: A meta-analysis

Cancer Causes and Control

Volumn 24, Issue 5, 2013, Pages 873-883

  Autier, Philippe ^a   Koechlin, Alice ^a   Boniol, Mathieu ^a   Mullie, Patrick ^a   Bolli, Geremia ^b   Rosenstock, Julio ^c   Boyle, Peter ^a  

^a INTERNATIONAL PREVENTION RESEARCH INSTITUTE   (France)

^b UNIVERSITY OF PERUGIA   (Italy)

^c DALLAS DIABETES AND ENDOCRINE CENTER AT MEDICAL CITY   (United States)

Author keywords

Breast cancer; C Peptide; Endogenous insulin; Meta analysis

Indexed keywords

C PEPTIDE; INSULIN;

ARTICLE; BODY MASS; BREAST CANCER; CANCER RISK; DIABETES MELLITUS; DISEASE ASSOCIATION; DOSE RESPONSE; HUMAN; INSULIN RESISTANCE; MENOPAUSE; OBESITY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RISK ASSESSMENT; SYSTEMATIC REVIEW;

BREAST NEOPLASMS; C-PEPTIDE; FEMALE; HUMANS; INSULIN; RISK ASSESSMENT;

EID: 84892785094     PISSN: 09575243     EISSN: 15737225     Source Type: Journal    
DOI: 10.1007/s10552-013-0164-6     Document Type: Article

References (40)

1. Adami HO, McLaughlin J, Ekbom A, Berne C, Silverman D, Hacker D, Persson I (1991) Cancer risk in patients with diabetes mellitus. Cancer Causes Control 2(5):307-314
2. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M (2008) Body-mass index and incidence of cancer: a systematic review and meta-Analysis of prospective observational studies. Lancet 371(9612):569-578
3. La Vecchia C, Giordano SH, Hortobagyi GN, Chabner B (2011) Overweight, obesity, diabetes, and risk of breast cancer: interlocking pieces of the puzzle. Oncologist 16(6):726-729
4. Belfiore A, Frasca F (2008) IGF and insulin receptor signalling in breast cancer. J Mammary Gland Biol Neoplasia 13(4):381-406
5. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, Mike Clarke M, Devereaux PJ, Kleijnen J, David Moher D (2009) The PRISMA statement for reporting systematic reviews and meta-Analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339:b2700
6. van Houwelingen HC, Arends LR, Stijnen T (2002) Advanced methods in meta-Analysis: multivariate approach and metaregression. Stat Med 21(4):589-624
7. R Development Core Team (2011) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna
8. Viechtbauer W (2010) Conducting meta-Analyses in R with the metafor package. J Stat Softw 36(3):1-48
9. Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50(4):1088-1101
10. Egger M, Smith GD, Phillips AN (1997) Meta-Analysis: principles and procedures. BMJ 315(7121):1533-1537
11. Macaskill P, Walter SD, Irwig L (2001) A comparison of methods to detect publication bias in meta-Analysis. Stat Med 20(4):641-654
12. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-Analysis. Stat Med 21(11):1539-1558
13. Yam D, Fink A, Mashiah A, Ben-Hur E (1996) Hyperinsulinemia in colon, stomach and breast cancer patients. Cancer Lett 104(2):129-132
14. Del Giudice ME, Fantus IG, Ezzat S, McKeown-Eyssen G, Page D, Goodwin PJ (1998) Insulin and related factors in premenopausal breast cancer risk. Breast Cancer Res Treat 47(2):111-120
15. Jernström H, Barrett-Connor E (1999) Obesity, weight change, fasting insulin, proinsulin, C-peptide, and insulin-like growth factor-1 levels in women with and without breast cancer: the Rancho Bernardo Study. J Womens Health Gend Based Med 8(10):1265-1272
16. Hirose K, Toyama T, Iwata H, Takezaki T, Hamajima N, Tajima K (2003) Insulin, insulin-like growth factor-I and breast cancer risk in Japanese women. Asian Pac J Cancer Prev 4(3):239-246
17. Lawlor DA, Smith GD, Ebrahim S (2004) Hyperinsulinaemia and increased risk of breast cancer: findings from the British Women's Heart and Health Study. Cancer Causes Control 15(3):267-275
18. Han C, Zhang HT, Du L, Liu X, Jing J, Zhao X, Yang X, Tian B (2005) Serum levels of leptin, insulin, and lipids in relation to breast cancer in China. Endocrine 26(1):19-24
19. Gonullu G, Ersoy C, Ersoy A, Evrensel T, Basturk B, Kurt E, Oral B, Gokgoz S, Manavoglu O (2005) Relation between insulin resistance and serum concentrations of IL-6 and TNF-Alpha in overweight or obese women with early stage breast cancer. Cytokine 31(4):264-269
20. Garmendia ML, Pereira A, Alvarado ME, Atalah E (2007) Relation between insulin resistance and breast cancer among Chilean women. Ann Epidemiol 17(6):403-409
21. Abbasi M, Tarafdari A, Esteghamati A, Vejdani K, Nakhjavani M (2010) Insulin resistance and breast carcinogenesis: a cross-sectional study among Iranian women with breast mass. Metab Syndr Relat Disord 8(5):411-416
22. Muti P, Quattrin T, Grant BJ, Krogh V, Micheli A, Schünemann HJ, Ram M, Freudenheim JL, Sieri S, Trevisan M, Berrino F (2002) Fasting glucose is a risk factor for breast cancer: a prospective study. Cancer Epidemiol Biomarkers Prev 11(11): 1361-1368
23. Sieri S,Muti P, Agnoli C, Berrino F, Pala V, Grioni S, Abagnato CA, Blandino G, Contiero P, Schunemann HJ, Krogh V (2012) Prospective study on the role of glucose metabolism in breast cancer occurrence. Int J Cancer 130(4):921-92924
24. Al-Delaimy WK, Flatt SW, Natarajan L, Laughlin GA, Rock CL, Gold EB, Caan BJ, Parker BA, Pierce JP (2011) IGF1 and risk of additional breast cancer in the WHEL study. Endocr Relat Cancer 18(2):235-244
25. Eliassen AH, Tworoger SS, Mantzoros CS, Pollak MN, Hankinson SE (2007) Circulating insulin and c-peptide levels and risk of breast cancer among predominately premenopausal women. Cancer Epidemiol Biomarkers Prev 16(1):161-164
26. Mink PJ, Shahar E, Rosamond WD, Alberg AJ, Folsom AR (2002) Serum insulin and glucose levels and breast cancer incidence: the atherosclerosis risk in communities study. Am J Epidemiol 156(4):349-352
27. Kaaks R, Lundin E, Rinaldi S, Manjer J, Biessy C, Söderberg S, Lenner P, Janzon L, Riboli E, Berglund G, Hallmans G (2002) Prospective study of IGF-I, IGF-binding proteins, and breast cancer risk, in Northern and Southern Sweden. Cancer Causes Control 13(4):307-316
28. Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Rohan TE, Manson JE,Li J,HoGY, XueX,Anderson GL,Kaplan RC,Harris TG, Howard BV, Wylie-Rosett J, Burk RD, Strickler HD (2009) Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 101(1):48-60
29. Kabat GC, Kim M, Caan BJ, Chlebowski RT, Gunter MJ, Ho GY, Rodriguez BL, Shikany JM, Strickler HD, Vitolins MZ, Rohan TE (2009) Repeated measures of serum glucose and insulin in relation to postmenopausal breast cancer. Int J Cancer 125(11):2704-2710
30. Capasso I, Esposito E, Pentimalli F, Crispo A, Montella M, GrimaldiM, De Marco M, Cavalcanti E, D'Aiuto M, Fucito A, Frasci G, Maurea N, Esposito G, Pedicini T, Vecchione A, D'Aiuto G, Giordano A (2011) Metabolic syndrome affects breast cancer risk in postmenopausal women: National Cancer Institute of Naples experience. Cancer Biol Ther 10(12):1240-1243
31. Bruning PF, Bonfrèr JM, van Noord PA, Hart AA, de Jong-Bakker M, Nooijen WJ (1992) Insulin resistance and breastcancer risk. Int J Cancer 52(4):511-516
32. Yang G, Lu G, Jin F, Dai Q, Best R, Shu XO, Chen JR, Pan XY, Shrubsole M, Zheng W (2001) Population-based, case-control study of blood C-peptide level and breast cancer risk. Cancer Epidemiol Biomarkers Prev 10(11):1207-1211
33. Malin A, Dai Q, Yu H, Shu XO, Jin F, Gao YT, Zheng W (2004) Evaluation of the synergistic effect of insulin resistance and insulin-like growth factors on the risk of breast carcinoma. Cancer 100(4):694-700
34. SchairerC, HillD, SturgeonSR, Fears T, PollakM,Mies C,ZieglerRG, Hoover RN, Sherman ME (2004) Serum concentrations of IGF-I, IGFBP-3 and c-peptide and risk of hyperplasia and cancer of the breast in postmenopausal women. Int J Cancer 108(5):773-779
35. Falk RT, Brinton LA, Madigan MP, Potischman N, Sturgeon SR, Malone KE, Daling JR (2006) Interrelationships between serum leptin, IGF-1, IGFBP3, C-peptide and prolactin and breast cancer risk in young women. Breast Cancer Res Treat 98(2):157-165
36. Fair AM, Montgomery K (2009) Energy balance, physical activity, and cancer risk. In: Verma M (ed) Methods of molecular biology, cancer epidemiology, vol 472. Humana Press, Totowa
37. Keinan-Boker L, Bueno De Mesquita HB, Kaaks R, Van Gils CH, Van Noord PA, Rinaldi S, Riboli E, Seidell JC, Grobbee DE, Peeters PH (2003) Circulating levels of insulin-like growth factor I, its binding proteins-1,-2,-3, C-peptide and risk of postmenopausal breast cancer. Int J Cancer 106(1):90-95
38. Verheus M, Peeters PH, Rinaldi S, Dossus L, Biessy C, Olsen A, Tjønneland A, Overvad K, Jeppesen M, Clavel-Chapelon F, Téhard B, Nagel G, Linseisen J, Boeing H, Lahmann PH, Arvaniti A, Psaltopoulou T, Trichopoulou A, Palli D, Tumino R, Panico S, Sacerdote C, Sieri S, van Gils CH, Bueno-de-Mesquita BH, González CA, Ardanaz E, Larranaga N, Garcia CM, Navarro C, Quirós JR, Key T, Allen N, Bingham S, Khaw KT, Slimani N, Riboli E, Kaaks R (2006) Serum C-peptide levels and breast cancer risk: results from the European Prospective Investigation into Cancer and Nutrition (EPIC). Int J Cancer 119(3):659-667
39. Toniolo P, Bruning PF, Akhmedkhanov A, Bonfrer JM, Koenig KL, Lukanova A, Shore RE, Zeleniuch-Jacquotte A (2000) Serum insulin-like growth factor-I and breast cancer. Int J Cancer 88(5): 828-832
40. Cust AE, Stocks T, Lukanova A, Lundin E, Hallmans G, Kaaks R, Jonsson H, Stattin P (2009) The influence of overweight and insulin resistance on breast cancer risk and tumour stage at diagnosis: a prospective study. Breast Cancer Res Treat 113(3):567-576